DELCATH SYSTEMS INC (DCTH) Stock News

Delcath Systems to Host First Quarter 2025 Earnings Call

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Beta Bionics Announces Board Appointment of Gerard Michel

Mentions: BBNX

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Analyst Expectations For Delcath Systems's Future

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Uncovering Potential: Delcath Systems's Earnings Preview

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Delcath Systems (NASDAQ:DCTH) just reported results for the second quarter of 2...

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems to Host Third Quarter 2024 Earnings Call

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024

DCTH stock results show that Delcath Systems missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems to Host Second Quarter 2024 Earnings Call